Already known worldwide for tackling some of the most difficult medical conditions, Mayo Clinic aims to ramp up its treatment options through a new strategic focus on biomanufacturing and biologics—drugs derived from living sources such as blood, enzymes, or tissue. In 2021, the health system tapped Julie Allickson to lead the effort. With nearly three decades of experience in cellular therapies and regenerative medicine, Allickson is uniquely suited to transform Mayo into a hub. “Gene, cellular, and gene-modified cellular therapies are currently—and will increasingly be—the future of medicine,” she says. “Promising therapeutic applications directly align with Mayo’s clinical priorities, including cancer, GI, cardiovascular diseases, and neurological disorders.”

Return to TCB 100 for 2023